Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di ricerca che confronta l'efficacia di diverse dosi del medicinale NNC0487-0111 nel ridurre lo zucchero nel sangue nelle persone con diabete di tipo 2

30 settembre 2026 aggiornato da: Novo Nordisk A/S

Sicurezza ed efficacia di NNC0487-0111 per via sottocutanea una volta alla settimana e per via orale una volta al giorno nei partecipanti con diabete di tipo 2: uno studio per la determinazione della dose

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

448

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Kyustendil, Bulgaria, 2500
        • Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
      • Kyustendil, Bulgaria, 2500
        • IPSOMC Dr. Miglena Rizova Ltd.
      • Plovdiv, Bulgaria, 4002
        • DCC Sveti Georgi EOOD
      • Plovdiv, Bulgaria, 4001
        • UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
      • Plovdiv, Bulgaria, 4002
        • Diagnostic-Consultative Centre "Sveti Georgi" Eood
      • Plovdiv, Bulgaria, 4001
        • UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
      • Sofia, Bulgaria, 1431
        • USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
      • Sofia, Bulgaria, 1431
        • UMHAT "Aleksandrovska"
      • Sofia, Bulgaria, 1000
        • Medical centre Regina Life Clinic EOOD
      • Sofia, Bulgaria, 1431
        • USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
      • Sofia, Bulgaria, 1431
        • UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
      • Varna, Bulgaria, 9020
        • AIPSMC Dr. Artin Magardichyan EOOD
      • Karlovac, Croazia, 47000
        • Opca bolnica Karlovac
      • Krapinske Toplice, Croazia, 49217
        • Specijalna bolnica Krapinske Toplice - Endokrinologija
      • Krapinske Toplice, Croazia, 49217
        • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
      • Osijek, Croazia, 31 000
        • Klinicki bolnicki centar Osijek_Endocrinology
      • Osijek, Croazia, 31 000
        • Klinicki bolnicki centar Osijek
      • Varaždin, Croazia, 42 000
        • Opca bolnica Varazdin_Endocrinology
      • Varaždin, Croazia, 42 000
        • Opca bolnica Varazdin
    • City of Zagreb
      • Zagreb, City of Zagreb, Croazia, 10000
        • Poliklinika Solmed
    • Primorje-Gorski Kotar County
      • Rijeka, Primorje-Gorski Kotar County, Croazia, 51 000
        • KBC Rijeka, Endokrinologija
      • Rijeka, Primorje-Gorski Kotar County, Croazia, 51 000
        • Clinical Hospital Centre Rijeka_Endocrinology
      • Elsterwerda, Germania, 04910
        • Zentrum für klinische Studien Südbrandenburg GmbH
      • Elsterwerda, Germania, 04910
        • Zentrum fuer klinische Studien Suedbrandenburg GmbH
      • Essen, Germania, 45136
        • InnoDiab Forschung GmbH
      • Hamburg, Germania, 22607
        • Wendisch/Dahl Hamburg
      • Hamburg, Germania, 22607
        • Wendisch - Dahl Hamburg - DZHW
      • Münster, Germania, 48145
        • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
      • Oldenburg in Holstein, Germania, 23758
        • RED-Institut für medizinische Forschung und Fortbildung GmbH
      • Aichi, Giappone, 468-0009
        • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
      • Chiba, Giappone, 261-0004
        • Tokuyama clinic_Diabetic internal medicine
      • Chiba, Giappone, 261-0004
        • Tokuyama clinic
      • Chiba-shi, Chiba, Giappone, 260-0804
        • Akaicho Clinic
      • Ibaraki, Giappone, 311-0113
        • Naka Kinen Clinic
      • Ibaraki, Giappone, 311-0113
        • Naka Kinen Clinic_Internal medicine
      • Tokyo, Giappone, 103-0027
        • Tokyo-Eki Center-building Clinic
      • Tokyo, Giappone, 104-0031
        • Fukuwa Clinic
      • Tokyo, Giappone, 103-0027
        • Tokyo-Eki Center-building Clinic_Internal Medicine
      • Tokyo, Giappone, 104-0031
        • Fukuwa Clinic_Internal Medicine
    • Miyazaki
      • Miyazaki, Miyazaki, Giappone, 880-0034
        • Heiwadai Hospital_Internal Medicine
      • Miyazaki, Miyazaki, Giappone, 880-0034
        • Heiwadai Hospital
      • Athens, Grecia, 115 25
        • Iatriko Psychicou Private Clinic
      • Athens, Grecia, 12462
        • U.G.H of Athens "Attikon"
      • Goudi/Athens, Grecia, 11527
        • "Laiko" General Hospital of Athens
      • Thessaloniki, Grecia, GR-54643
        • EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
      • Thessaloniki, Grecia, GR-57001
        • "Thermi" Private Hosital
      • Thessaloniki, Grecia, 564 29
        • 424 Military General Training Hospital
      • Thessaloniki, Grecia, 57001
        • "Thermi" Private Hosital
      • Thessaloniki, Grecia, 54645
        • EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
      • Thessaloniki, Grecia, 564 29
        • 424 Military General Training Hospital - 2nd Department of Internal Medicine
      • Bialystok, Polonia, 15-375
        • Specderm Poznańska Spółka Jawna
      • Lublin, Polonia, 20-718
        • EKAMED sp. z o.o.
      • Ruda Śląska, Polonia, 41-709
        • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
      • Warsaw, Polonia, 02-507
        • PANSTWOWY INSTYTUT MEDYCZNY MSWiA
    • Gornoslaskie
      • Ruda Śląska, Gornoslaskie, Polonia, 41-709
        • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polonia, 31-261
        • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
      • Oświęcim, Lesser Poland Voivodeship, Polonia, 32-600
        • Formed 2 Sp. z o.o.
    • Lower Silesian Voivodeship
      • Legnica, Lower Silesian Voivodeship, Polonia, 59-220
        • Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
      • Legnica, Lower Silesian Voivodeship, Polonia, 59-220
        • Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polonia, 20-718
        • EKAMED sp. z o.o.
    • Masovian Voivodeship
      • Siedlce, Masovian Voivodeship, Polonia, 08-110
        • ETG Siedlce
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polonia, 15-879
        • NZOZ Vita-Diabetica Malgorzata Buraczyk
      • Bialystok, Podlaskie Voivodeship, Polonia, 15-375
        • Specderm Poznanska Sp. j.
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polonia, 90-302
        • Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
      • Brasov, Romania, 500101
        • Mariodiab Clinic SRL
      • Timișoara, Romania, 300723
        • Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
      • Timișoara, Romania, 300288
        • Cabinet Medical Dr Geru SRL
    • Bihor County
      • Oradea, Bihor County, Romania, 410025
        • SC Grand Med SRL
      • Oradea, Bihor County, Romania, 410159
        • Grandmed SRL
    • Bucharest
      • Bucharest, Bucharest, Romania, 020475
        • Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
    • Bucurestii
      • Bucharest, Bucurestii, Romania, 020475
        • Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
    • Cluj
      • Cluj-Napoca, Cluj, Romania, 400006
        • Spitalul Clinic Judetean Urgenta Cluj-Napoca
    • Mureș County
      • Târgu Mureş, Mureș County, Romania, 540142
        • Sc Mediab Srl
    • Prahova
      • Ploieşti, Prahova, Romania, 100018
        • Novus Medical Clinica SRL
      • Poprad, Slovacchia, 05801
        • DENTAVIA s.r.o.
      • Prešov, Slovacchia, 080 01
        • DIABETOL, s.r.o.
      • Rimavská Sobota, Slovacchia, 979 01
        • OLIVER - MED s.r.o.
      • Žilina, Slovacchia, 010 01
        • MEDIVASA, s.r.o., Diabetologicka ambulancia
    • Slovak Republic
      • Šahy, Slovak Republic, Slovacchia, 93601
        • Peter Farkas MD, s.r.o.
      • A Coruña, Spagna, 15006
        • Complejo Hospitalario Universitario A Coruña
      • Barcelona, Spagna, 08036
        • Hospital Clinic i Provincial
      • Castilleja de la Cuesta, Spagna, 41950
        • Hospital Vithas Sevilla
      • Madrid, Spagna, 28007
        • Hospital Gregorio Marañón
      • Pontevedra, Spagna
        • Complejo Hospitalario de Pontevedra - Hospital de Montecelo
      • Santander, Spagna, 39008
        • Hospital Universitario Marqués de Valdecilla
      • Seville, Spagna, 41003
        • Clínica Nuevas Tecnologías en Diabetes y Endocrinología
      • Seville, Spagna, 41010
        • Hospital Infanta Luisa
      • Seville, Spagna, 41950
        • Hospital Nisa Sevilla Aljarafe
      • Seville, Spagna, 41010
        • H. Infanta Luisa_Endocrino y Obesidad
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • Uni of Alabama at Birmingham
    • California
      • Los Angeles, California, Stati Uniti, 90057
        • Velocity Clin Research LA
      • Santa Ana, California, Stati Uniti, 92701
        • Southern Cal Clinical Research
    • Connecticut
      • Waterbury, Connecticut, Stati Uniti, 06708
        • Chase Medical Research LLC
    • Florida
      • Fleming Island, Florida, Stati Uniti, 32003
        • Fleming Island Ctr for Clin Res
      • Hollywood, Florida, Stati Uniti, 33024
        • Encore Medical Research LLC
      • Miramar, Florida, Stati Uniti, 33027
        • South Broward Research LLC
      • Orlando, Florida, Stati Uniti, 32825
        • Florida Inst For Clin Res
      • Orlando, Florida, Stati Uniti, 32825
        • Florida Institute for Clinical research
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60607
        • Cedar-Crosse Research Center
    • Kansas
      • Topeka, Kansas, Stati Uniti, 66606
        • Cotton O'Neil Clinical Research Center
    • Kentucky
      • Paducah, Kentucky, Stati Uniti, 42001
        • Advanced Internal Medicine, PLLC
    • Maryland
      • Hyattsville, Maryland, Stati Uniti, 20782
        • Medstar Research Institute_Hyattsville
      • Oxon Hill, Maryland, Stati Uniti, 20745
        • MD Medical Research
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02115
        • Brigham & Women's Hospital
      • Methuen, Massachusetts, Stati Uniti, 01844
        • ActivMed Practice & Research LLC
    • Michigan
      • Troy, Michigan, Stati Uniti, 48098
        • Arcturus Healthcare, PLC
      • Troy, Michigan, Stati Uniti, 48098
        • Arcturus HC PLC Troy Med Res
    • Missouri
      • Chesterfield, Missouri, Stati Uniti, 63005
        • Clinical Research Professionals
      • City of Saint Peters, Missouri, Stati Uniti, 63303
        • StudyMetrix Research LLC
    • New York
      • Albany, New York, Stati Uniti, 12203
        • AMC Community Endocrinology
    • North Carolina
      • Morehead City, North Carolina, Stati Uniti, 28557
        • Centricity Rsrch MHCity Multi
      • Statesville, North Carolina, Stati Uniti, 28625
        • Piedmont Healthcare/Research
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58104
        • Lillestol Research LLC
      • Fargo, North Dakota, Stati Uniti, 58104
        • Plains Clinical Research Center, LLC_Fargo
    • Oklahoma
      • Norman, Oklahoma, Stati Uniti, 73069
        • Alliance for Multispec Res
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19107-6810
        • Jefferson Endocrinology Assocs
      • Pittsburgh, Pennsylvania, Stati Uniti, 15236
        • Preferred Primary Care Physicians_Pittsburgh
    • South Dakota
      • Rapid City, South Dakota, Stati Uniti, 57702
        • Health Concepts
    • Tennessee
      • Kingsport, Tennessee, Stati Uniti, 37660
        • Holston Medical Group
      • Nashville, Tennessee, Stati Uniti, 37203
        • Clinical Research Associates
      • Nashville, Tennessee, Stati Uniti, 37203
        • MidState Endocrine Associates
    • Texas
      • Dallas, Texas, Stati Uniti, 75230
        • Velocity Clinical Res-Dallas
      • Houston, Texas, Stati Uniti, 77024
        • Victorium Clinical Research
      • Houston, Texas, Stati Uniti, 77079
        • PlanIt Research, PLLC
      • Houston, Texas, Stati Uniti, 77061
        • Synergy Groups Medical
      • Lampasas, Texas, Stati Uniti, 76550
        • Radiance Clinical Research
      • McKinney, Texas, Stati Uniti, 75069
        • Tekton Research
      • Waco, Texas, Stati Uniti, 76708
        • Hillcrest Family Health Center
      • Budapest, Ungheria, 1106
        • Bajcsy-Zsilinszky Kórház
      • Budapest, Ungheria, 1134
        • MH Egészségügyi Központ
      • Debrecen, Ungheria, 4031
        • Debreceni Egyetem
      • Debrecen, Ungheria, H-4031
        • Debreceni Egyetem
      • Debrecen, Ungheria, H-4032
        • Debreceni Egyetem
      • Gyula, Ungheria, 5700
        • Békés Megyei Központi Kórház
      • Kaposvár, Ungheria, 7400
        • Somogy Vármegyei Kaposi Mór Oktató Kórház
      • Kaposvár, Ungheria, H-7400
        • Somogy Vármegyei Kaposi Mór Oktató Kórház
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungheria, 4032
        • Debreceni Egyetem

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
  • Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
  • HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
  • Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
  • Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo subcutaneous

Placebo for subcutaneous treatment

NNC0487-0111 placebo administered subcutanously (under the skin)

Sperimentale: NNC0487-0111 subcutaneous dose 1

NNC0487-0111 subcutaneous dose 1 treatment

NNC0487-0111 administered subcutanously (under the skin)

Sperimentale: NNC0487-0111 subcutaneous dose 2

NNC0487-0111 subcutaneous dose 2 treatment

NNC0487-0111 administered subcutanously (under the skin)

Sperimentale: NNC0487-0111 subcutaneous dose 3

NNC0487-0111 subcutaneous dose 3 treatment

NNC0487-0111 administered subcutanously (under the skin)

Sperimentale: NNC0487-0111 subcutaneous dose 4

NNC0487-0111 subcutaneous dose 4 treatment

NNC0487-0111 administered subcutanously (under the skin)

Sperimentale: NNC0487-0111 subcutaneous dose 5

NNC0487-0111 subcutaneous dose 5 treatment

NNC0487-0111 administered subcutanously (under the skin)

Sperimentale: NNC0487-0111 subcutaneous dose 6

NNC0487-0111 subcutaneous dose 6 treatment

NNC0487-0111 administered subcutanously (under the skin)

Comparatore placebo: Placebo oral

Placebo for oral treatment

NNC0487-0111 placebo administered orally (in the mouth)

Sperimentale: NNC0487-0111 oral dose 1

NNC0487-0111 oral dose 1 treatment

NNC0487-0111 administered orally (in the mouth)

Sperimentale: NNC0487-0111 oral dose 2

NNC0487-0111 oral dose 2 treatment

NNC0487-0111 administered orally (in the mouth)

Sperimentale: NNC0487-0111 oral dose 3

NNC0487-0111 oral dose 3 treatment

NNC0487-0111 administered orally (in the mouth)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in HbA1c
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

percent point

From baseline (week 0) to end of treatment (week 36)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Relative change in body weight
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

percent

From baseline (week 0) to end of treatment (week 36)
Change in body weight
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

kg

From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

mmol/L

From baseline (week 0) to end of treatment (week 36)
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

percent points

From baseline (week 0) to end of treatment (week 36)
Change in body mass index (BMI)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

kg/m^2

From baseline (week 0) to end of treatment (week 36)
Change in waist circumference
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

cm

From baseline (week 0) to end of treatment (week 36)
Change in systolic blood pressure (SBP)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

mmHg

From baseline (week 0) to end of treatment (week 36)
Change in average 24-hour systolic blood pressure (SBP)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

mmHg

From baseline (week 0) to end of treatment (week 36)
Change in high sensitivity C-Reactive Protein (hsCRP)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in total cholesterol
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in high-density lipoprotein (HDL) cholesterol
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in low-density lipoprotein (LDL) cholesterol
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in triglycerides
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Number of adverse events
Lasso di tempo: From baseline (week 0) to end of study (week 40)

Count of events

From baseline (week 0) to end of study (week 40)
Change in Urinary Albumin/Creatinine Ratio (UACR)
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

Ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
Lasso di tempo: At end of treatment (week 36)

Count of participant

At end of treatment (week 36)
Change in eGFR creatinine- and cystatin C based CKD-EPI
Lasso di tempo: From baseline (week 0) to end of treatment (week 36)

mL/min/1.73 m^2

From baseline (week 0) to end of treatment (week 36)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 agosto 2024

Completamento primario (Effettivo)

1 ottobre 2025

Completamento dello studio (Effettivo)

24 ottobre 2025

Date di iscrizione allo studio

Primo inviato

5 agosto 2024

Primo inviato che soddisfa i criteri di controllo qualità

5 agosto 2024

Primo Inserito (Effettivo)

7 agosto 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NN9490-7678
  • U1111-1296-9708 (Altro identificatore: World Health Organization (WHO))
  • 2023-509412-28 (Altro identificatore: European Medical Agency (EMA))
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .